Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.…
Lavipharm: Αύξηση 28% στις πωλήσεις και 14,3% στα καθαρά κέρδη το 9μηνο
Lavipharm (ATH: LAVI) is listed on Athens Exchange, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 306 employees.
The shares were at 1.446 EUR on 20 November 2026, up 78.5% over 52 weeks. Its 52-week range is 0.7950 EUR to 1.734 EUR: the price is 16.6% below the high and 81.9% above the low.
At a market capitalisation of 246.95M EUR, it trades at 48.2 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 97% for LAVI. It pays a dividend yielding 1.34% (it pays out 68% of its earnings), against a median of 1.95% among the dividend payers in that peer group.
Lavipharm reports return on equity of 10.6%, an operating margin of 12.8% and revenue up 41.3% year over year.
Its debt exceeds its cash by 37.66M EUR, a debt-to-equity ratio of 0.58. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health.
No upcoming events tracked.